Janssen Vaccines & Prevention B.V.
- Country
- ๐ณ๐ฑNetherlands
- Ownership
- -
- Established
- 2000-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.crucell.com
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
- Conditions
- Lower Respiratory Tract DiseaseRespiratory Syncytial Viruses
- Interventions
- Biological: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preFBiological: Placebo
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 25236
- Registration Number
- NCT04908683
- Locations
- ๐บ๐ธ
New Horizon Research Center, Miami, Florida, United States
๐บ๐ธSuncoast Research Associates, LLC, Miami, Florida, United States
๐บ๐ธClinical Site Partners, LLC, Miami, Florida, United States
A Study of Ad26.COV2.S in Healthy Adults (COVID-19)
- Conditions
- Healthy
- Interventions
- Biological: Ad26.COV2.S
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 380
- Registration Number
- NCT04894305
- Locations
- ๐ณ๐ฑ
PRA Health Sciences, Groningen, Netherlands
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 51
- Registration Number
- NCT04765384
- Locations
- ๐ง๐ท
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, Brazil
๐บ๐ธMedpharmics, LLC, Albuquerque, New Mexico, United States
๐บ๐ธMaximos OB/GYN, League City, Texas, United States
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
- Conditions
- Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 31835
- Registration Number
- NCT04614948
- Locations
- ๐บ๐ธ
Avail Clinical Research, LLC, DeLand, Florida, United States
๐บ๐ธCompass Research, Melbourne, Melbourne, Florida, United States
๐บ๐ธSuncoast Research Group, Miami, Florida, United States
A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 4031
- Registration Number
- NCT04556526
- Locations
- ๐ท๐ผ
Gisenyi Hospital, Gysenyi, Rwanda
๐ท๐ผGihundwe District Hospital, Cuangugu, Rwanda
๐ท๐ผCenter for Family Health Research/Project San Francisco, Kigali, Rwanda
A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents
- Conditions
- Healthy
- Interventions
- Biological: Ad26.COV2.SOther: Placebo
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 635
- Registration Number
- NCT04535453
- Locations
- ๐ฉ๐ช
CTC North GmbH & Co. KG, Am Universitรคtsklinikum Hamburg-Eppendorf, Hamburg, Germany
๐ณ๐ฑUMCU, Utrecht, Netherlands
๐ช๐ธHosp. Univ. La Paz, Madrid, Spain
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
- Conditions
- Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
- Interventions
- Other: Placebo
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 44325
- Registration Number
- NCT04505722
- Locations
- ๐บ๐ธ
Synexus Clinical Research US Inc, Murray, Utah, United States
๐บ๐ธUniversity of Alabama Birmingham, Birmingham, Alabama, United States
๐บ๐ธAlabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States
A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 459
- Registration Number
- NCT04453202
- Locations
- ๐บ๐ธ
Optimal Research, Rockville, Maryland, United States
๐บ๐ธClinical Research of South Florida, an AMR Company, Coral Gables, Florida, United States
๐บ๐ธHeartland Research Associates, an AMR Company, El Dorado, Kansas, United States
A Study of Ad26.COV2.S in Adults (COVID-19)
- Conditions
- Covid-19 Prevention
- Interventions
- Biological: Placebo
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 1085
- Registration Number
- NCT04436276
- Locations
- ๐บ๐ธ
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
๐ง๐ชUZA-SGS, Edegem, Belgium
๐บ๐ธOptimal Research, Austin, Texas, United States
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
- Conditions
- Ebola
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 974
- Registration Number
- NCT04228783
- Locations
- ๐บ๐ธ
Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States
๐บ๐ธCoastal Clinical Research, Inc, Mobile, Alabama, United States
๐บ๐ธCentral Kentucky Research Associates, Inc., Lexington, Kentucky, United States